HealthBeacon Plc is floating on the Euronext Growth Market, in Dublin, after raising €25mln from investors.
Alongside the Dublin float the company, which develops digital products for at-home injectable medicines, is issuing some 4.27mln new shares priced at €5.85 each. The IPO values the company at €100mln.
DeepVerge PLC (AIM:DVRG) said it completed the development of its third-generation compact Microtox PD Coronavirus (COVID-19) detection system, which is able to identify SARS-CoV-2 and a range of pathogens at local, regional and national levels.
The upgraded system, which was developed by Deepverge's Modern Water unit, is scheduled for launch in the first quarter of 2022, the company said in a statement.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) said its subsidiary hVIVO signed a contract worth US$13.4mln (£10.13mln) with a US biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.
The study is expected to start in the second half of 2022 and will be conducted at hVIVO's state-of-the-art quarantine facilities in London, the company said in a statement.
Aladdin Healthcare SE said it has gained approval from OTC Markets Group Inc to have the company’s shares quoted on the OTCQB market under the symbol ALDNF, moving up from its current OTC Pink Market listing.
Along with the new US stock quotation, Aladdin Healthcare is re-positioning its business through merger or acquisition opportunities to transform its commercial viability and in turn monetise its AI and blockchain technologies.
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it is to present microbiome analyses from phase II clinical trials of its drug Blautix, revealing its impact on the two major forms of irritable bowel syndrome – IBS-C and IBS-D.
The results, to be presented in an e-poster at the Gastro 2021 conference starting December 11, chart changes in gut microbiome structure following administration of the 4D live biotherapeutic. The data is from new faecal microbiome analyses.
Apollon Formularies (AQSE:APOL) PLC said it started treating its first cancer patients using cannabis-based therapies at the International Cancer and Chronic Pain Institute in Kingston, Jamaica.
With expertise in cannabinoid medicine, the team will be led by Dr Margaret Dingle Spence.
A biomarker study from a Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) phase I/II cancer trial yielded what chief executive Dr Markku Jalkanen described as ‘exciting' findings that should help identify which patients will respond best to its drug bexmarilimab when it is used on its own.
The top-line analysis of the latest patient feedback reveals bexmarilimab ignites a response from those that have not traditionally benefited from current immunotherapy treatments.
WisdomTree launched an exchange-traded fund (ETF) in London and Frankfurt that tracks an index of leading companies engaged in genetics and biotechnology.
The WisdomTree BioRevolution UCITS ETF (LSE:WDNA), which has an expense ratio of 0.45%, tracks the WisdomTree BioRevolution ESG Screened Index.
Redx Pharma PLC (AIM:REDX) said a US$10mln milestone payment has been triggered under its oncology research collaboration with Nasdaq-listed Jazz Pharma, which has now moved into its second year.
Redx, which has realised US$20mln so far from the Jazz relationship, could potentially earn US$200mln from the tie-up for negotiating certain development, regulatory and commercial hurdles.
Is there a second mystery bidder out there for Clinigen Group PLC (AIM:CLIN)? Based on the share price movement, the market is betting there is.
The group on Wednesday confirmed it agreed to be bought out by private equity firm Triton Investment Management in a deal that values the speciality pharma group at £1.2bn.
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it presented in vitro data demonstrating antiviral activity of its lead asset SNG001 against multiple variants of SARS-CoV-2 and clinical biomarker data which showed inhaled SNG001 stimulates lung antiviral responses.
The respiratory company made the poster and oral presentations to the European Scientific Working Group in Influenza conference.
AstraZeneca PLC (LSE:AZN) has agreed a licensing deal potentially worth almost as much as the market capitalisation of the Californian biotech it is teaming up with.
The transactions could see AZ hand over as much as US$3.585bn to Ionis Pharmaceuticals (NASDAQ:IONS) Inc (current valuation US$3.88bn).
AstraZeneca PLC (LSE:AZN)’s acquisition of Alexion Pharmaceuticals (NASDAQ:ALXN) Inc was the highlight of a third-quarter that saw UK companies splash out £32.8bn on acquisitions.
Figures from the Office for National Statistics (ONS) show that while the three months to the end of September saw a decline in merger & acquisition (M&A) deals to 136 a month from 164 in the preceding quarter, UK companies flexed their muscle overseas a bit more, with foreign businesses acquired valued at £32.8bn, well up from £8.2bn in the preceding quarter.
A drug co-developed by GlaxoSmithKline PLC (LSE:GSK) to treat moderate-to-severe Coronavirus (COVID-19) cases is effective against the omicron variant, according to a second batch of positive pre-clinical data.
The latest results from a test of sotrovimab against a pseudo-virus tally with the earlier information released on December 2.
The second quarter of next year looks likely to be a busy time for the research team at Evgen Pharma PLC (AIM:EVG).
The company’s half-year results statement has confirmed that a phase Ib/II study of the use of SFX-01 in glioblastoma is likely to go ahead in the period.
IXICO PLC (AIM:IXI, OTC:PHYOF) reported a 34% increase in underlying annual profits and said its analytical offering will be enhanced further during the next 12 months as a new algorithm platform is launched.
Alongside this, the AI neuroimaging company said the launch of its next-generation cloud-based data capture and analysis platform remains on track for the second half of the new financial year.
Oncimmune Holdings PLC (AIM:ONC) said its ImmunoINSIGHTS pharma services business is gaining significant commercial traction following a record quarter.
That said, the operation still doesn’t seem to have tapped its full potential and will increase its sales team to meet expected demand.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received promising data from its ongoing Phase I/II clinical trial for the treatment of burn wound infections with RECCE® 327 (R327), its proprietary synthetic anti-infective.
The West Australian Health Department sponsored clinical trial at Fiona Stanley Hospital is assessing the safety and efficacy of R327 in patients with infected burn wounds under Trial ID ACTRN12621000412831.
OKYO Pharma Ltd, the biopharmaceutical company developing medicine targeting people with eye disease and ocular pain, says it will know for certain if its lead asset, OK-101, is an effective treatment by mid-2023.
The eyedrop drug could potentially skip straight through into phase two human trials if its investigational new drug application (IND), expected to be filed in the third quarter of 2022, is approved.
Kanabo Group PLC (LSE:KNB) has seen its share price climb on the back of a statement noting that the UK medical regulator’s plans for e-cigarettes to help people quit smoking.
The medical cannabis and research and development company put out a statement noting the UK’s Medicines and Healthcare Products Regulatory Agency had announced that the NHS “could soon prescribe e-cigarettes to help patients stop smoking tobacco products”.
Ondine Biomedical Inc said its shares started trading on London’s AIM market today.
The Canadian company has pioneered a new non-antibiotic antimicrobial technology called photodisinfection which rapidly destroys pathogens - including SARS-CoV-2 - without causing resistance.
Incanthera plc (AQSE:INC) has started talks for the commercial rights to Sol, its skin cancer formulation and lead product, with another two companies, the group said alongside its interim results.
Discussions with two previously announced global cosmetic companies are also continuing to progress, said the specialist oncology company.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) has hailed positive results from a phase IIa study of a new seasonal flu treatment, developed by SAB Biotherapeutics.
The randomised, placebo-controlled trial was carried out at a specialist facility operated by Open Orphan’s subsidiary, hVIVO, using its influenza human challenge study model.
Sativa Wellness Group Inc (AQSE:SWEL, CSE:SWEL, OTC:SCNNF) told investors that it had a record week for bookings last week, exceeding £13.8mln revenue in the eleven months to the end of November.
The CBD wellness company said that several days exceeded previous records, with there now being over 140 clinics in the Goodbody network.
Cellular Goods PLC (LSE:CBX) has appointed Anna Chokina as chief executive to manage the company's next stage of development following the launch of its inaugural cannabidiol (CBD) based product range last week.
Chokina has more than 20 years of experience in senior roles in the consumer goods industry. She successfully launched Avon's first-ever lines of CBD-based products for the personal care and skincare market and before that she was General Manager in Russia for L'Oreal.
Redx Pharma PLC (AIM:REDX) is teaming up with a company that will help it select the ‘right’ patients for its US cancer clinical trial.
It will work with Caris Life Sciences to assess an individual’s patient's molecular tumour profile against the trial's eligibility requirements.
Induction Healthcare Group PLC (AIM:INHC) said its remote consultation service has launched a new healthcare function which has been rolled out across the UK.
The Induction Attend Anywhere platform now also supports clinical group consultations, where one-to-one consultations take place within a group setting of patients with similar clinical conditions, the company said in a statement.
Poolbeg Pharma PLC (AIM:POLB) has signed an option agreement to licence a vaccine for an infectious disease called melioidosis.
Poolbeg has signed the agreement for MelioVac with University College Dublin and its inventor, associate professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.
Okyo Pharma Ltd (LSE:OKYO, OTCQB:EMMLF) said its treatment for dry eye disease looks set to go straight into a phase II clinical trial in the fourth quarter of next year once its investigational new drug (IND) application has been approved.
The IND for lead asset OK-101 will be submitted in the third quarter of 2022.